학술논문

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer.
Document Type
Article
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p1105-1105, 1p
Subject
Language
ISSN
0732183X